Mitoxantrone Liposome Combination Therapy for AML Relapse Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) primarily rely on chemotherapy, with limited efficacy and high relapse rates, and there is a need for more effective therapeutic options.
Innovation Solution
The use of mitoxantrone liposome combined with cytarabine, or further combined with drugs like homoharringtonine or venetoclax, to enhance therapeutic effects in treating AML.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy regimens (cytarabine combined with anthracyclines) are used for AML treatment, then induction therapy can achieve complete remission in 60-80% of patients, but most patients will relapse after entering remission and only about less than 50% can achieve a second remission
Solution Approach 1:
The patent uses liposomal formulation to create a composite drug delivery system that combines mitoxantrone with lipid bilayer structures. This composite approach allows for controlled release and sustained therapeutic levels, addressing the relapse problem by maintaining effective drug concentrations over time rather than single-dose chemotherapy
Solution Approach 2:
The patent segments the treatment approach by using liposomal encapsulation to divide drug delivery into controlled releases. The liposome structure breaks down gradually, releasing mitoxantrone in a sustained manner, which prevents early relapse by maintaining therapeutic pressure on leukemia cells throughout the treatment cycle
2Reliability
If mitoxantrone liposome is used to improve therapeutic effect and reduce relapse, then the treatment complexity and manufacturing difficulty increase compared to conventional chemotherapy
Solution Approach 1:
The liposome acts as an intermediary carrier that simplifies the delivery of mitoxantrone. Rather than administering raw chemotherapy agents, the liposomal formulation serves as a mediator that controls drug release, protects the drug, and targets delivery, thereby improving efficacy while managing complexity through a single integrated delivery system
Data Source
AI summary
The use of mitoxantrone liposome combined with cytarabine, or further combined with other drugs, such as homoharringtonine or venetoclax, in the preparation of drugs used for treating acute myeloid leukemia (AML). Provided is a method of treating AML, the method comprising administering to an AML patient a pharmaceutical composition comprising mitoxantrone liposome and cytarabine, wherein the pharmaceutical composition may also comprise homoharringtonine or venetoclax.